Targeting protein-protein interaction by small molecules.

Protein-protein interactions (PPIs) are critical regulatory events in physiology and pathology, and they represent an important target space for pharmacological intervention. However, targeting PPIs with small molecules is challenging owing to the large surface area involved in protein-protein binding and the lack of obvious small-molecule-binding pockets at many protein-protein interfaces. Nonetheless, successful examples of small-molecule modulators of PPIs have been growing in recent years. This article reviews some of the recent advances in the discovery of small-molecule regulators of PPIs that involve key oncogenic proteins. Our discussion focuses on the three key modes of action for these small-molecule modulators: orthosteric inhibition, allosteric regulation, and interfacial binding/stabilization. Understanding the opportunities and challenges of these diverse mechanisms will help guide future efforts in developing small-molecule modulators against PPIs.

[1]  U. Rapp,et al.  Active Ras induces heterodimerization of cRaf and BRaf. , 2001, Cancer research.

[2]  Zhaoyang Wen,et al.  Discovery of a potent small-molecule antagonist of inhibitor of apoptosis (IAP) proteins and clinical candidate for the treatment of cancer (GDC-0152). , 2012, Journal of medicinal chemistry.

[3]  J. Huret,et al.  An Atlas on Chromosomes in Hematological Malignancies. Example: 11q23 and MLL partners , 2001, Leukemia.

[4]  S. Korsmeyer,et al.  Activation of Apoptosis in Vivo by a Hydrocarbon-Stapled BH3 Helix , 2004, Science.

[5]  Roger L. Williams,et al.  Tumour prevention by a single antibody domain targeting the interaction of signal transduction proteins with RAS , 2007, The EMBO journal.

[6]  M. Willingham,et al.  In vivo regulation of monomer-tetramer conversion of pyruvate kinase subtype M2 by glucose is mediated via fructose 1,6-bisphosphate. , 1991, The Journal of biological chemistry.

[7]  M. Belvin,et al.  RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth , 2010, Nature.

[8]  C. V. van Veelen,et al.  Isozymes of pyruvate kinase from human brain, meningiomas, and malignant gliomas. , 1978, Cancer research.

[9]  S. Robson,et al.  Inhibition of BET recruitment to chromatin as an effective treatment for MLL-fusion leukaemia , 2011, Nature.

[10]  Marc Therrien,et al.  A dimerization-dependent mechanism drives RAF catalytic activation , 2009, Nature.

[11]  Jolanta Grembecka,et al.  Molecular Basis of the Mixed Lineage Leukemia-Menin Interaction , 2010, The Journal of Biological Chemistry.

[12]  M. Lei,et al.  The same pocket in menin binds both MLL and JUND but has opposite effects on transcription , 2012, Nature.

[13]  M. Heuser,et al.  Linkage of Meis1 leukemogenic activity to multiple downstream effectors including Trib2 and Ccl3. , 2008, Experimental hematology.

[14]  B. Stoddard,et al.  The allosteric regulation of pyruvate kinase by fructose-1,6-bisphosphate. , 1998, Structure.

[15]  L. Johnson,et al.  The structural basis for control of eukaryotic protein kinases. , 2012, Annual review of biochemistry.

[16]  Mark S. Boguski,et al.  Proteins regulating Ras and its relatives , 1993, Nature.

[17]  I. Vetter,et al.  The Guanine Nucleotide-Binding Switch in Three Dimensions , 2001, Science.

[18]  Louis Renault,et al.  Arf, Arl, Arp and Sar proteins: a family of GTP‐binding proteins with a structural device for ‘front–back’ communication , 2002, EMBO reports.

[19]  Arndt Borkhardt,et al.  Hoxa9 and Meis1 Are Key Targets for MLL-ENL-Mediated Cellular Immortalization , 2004, Molecular and Cellular Biology.

[20]  P. Bamborough,et al.  Discovery and characterization of small molecule inhibitors of the BET family bromodomains. , 2011, Journal of medicinal chemistry.

[21]  J. Whelan Stapled peptide induces cancer cell death. , 2004, Drug discovery today.

[22]  M. Jacobson,et al.  Binding-Site Assessment by Virtual Fragment Screening , 2010, PloS one.

[23]  Patrick A. Curmi,et al.  Insight into tubulin regulation from a complex with colchicine and a stathmin-like domain , 2004, Nature.

[24]  C. Croce,et al.  Upregulation of Meis1 and HoxA9 in acute lymphocytic leukemias with the t(4 : 11) abnormality , 2001, Oncogene.

[25]  L. Cantley,et al.  Understanding the Warburg Effect: The Metabolic Requirements of Cell Proliferation , 2009, Science.

[26]  Tina N. Davis,et al.  A stapled p53 helix overcomes HDMX-mediated suppression of p53. , 2010, Cancer cell.

[27]  G. Sauvageau,et al.  Mice bearing a targeted interruption of the homeobox gene HOXA9 have defects in myeloid, erythroid, and lymphoid hematopoiesis. , 1997, Blood.

[28]  Dean W. Felsher,et al.  Combined Inactivation of MYC and K-Ras Oncogenes Reverses Tumorigenesis in Lung Adenocarcinomas and Lymphomas , 2008, PloS one.

[29]  Chi V. Dang,et al.  Otto Warburg's contributions to current concepts of cancer metabolism , 2011, Nature Reviews Cancer.

[30]  Stuart L. Schreiber,et al.  Structure of the FKBP12-Rapamycin Complex Interacting with Binding Domain of Human FRAP , 1996, Science.

[31]  David R. Liu,et al.  DNA-Templated Organic Synthesis and Selection of a Library of Macrocycles , 2004, Science.

[32]  W. Macon,et al.  T-cell-rich large-B-cell lymphomas contain non-activated CD8+ cytolytic T cells, show increased tumor cell apoptosis, and have lower Bcl-2 expression than diffuse large-B-cell lymphomas. , 1998, The American journal of pathology.

[33]  Christian M. Metallo,et al.  Pyruvate kinase M2 activators promote tetramer formation and suppress tumorigenesis , 2012, Nature chemical biology.

[34]  M. Cleary,et al.  Transformation of myeloid progenitors by MLL oncoproteins is dependent on Hoxa7 and Hoxa9. , 2003, Genes & development.

[35]  T. Graeber,et al.  An integrated approach to dissecting oncogene addiction implicates a Myb-coordinated self-renewal program as essential for leukemia maintenance. , 2011, Genes & development.

[36]  J. Drews,et al.  Drug Development: The role of innovation in drug development , 1997, Nature Biotechnology.

[37]  B. Brandhuber,et al.  Crystal Structure of Human AKT1 with an Allosteric Inhibitor Reveals a New Mode of Kinase Inhibition , 2010, PloS one.

[38]  T. Mak,et al.  Regulation of cancer cell metabolism , 2011, Nature Reviews Cancer.

[39]  J. Hess MLL: a histone methyltransferase disrupted in leukemia. , 2004, Trends in molecular medicine.

[40]  I. Mellman,et al.  Small-molecule ligands bind to a distinct pocket in Ras and inhibit SOS-mediated nucleotide exchange activity , 2012, Proceedings of the National Academy of Sciences.

[41]  R. Marais,et al.  Melanoma biology and new targeted therapy , 2007, Nature.

[42]  E. Sztul,et al.  Dissecting the role of the ARF guanine nucleotide exchange factor GBF1 in Golgi biogenesis and protein trafficking , 2007, Journal of Cell Science.

[43]  R. Young,et al.  BET Bromodomain Inhibition as a Therapeutic Strategy to Target c-Myc , 2011, Cell.

[44]  P. D. Dal Cin,et al.  BRD4 bromodomain gene rearrangement in aggressive carcinoma with translocation t(15;19). , 2001, The American journal of pathology.

[45]  W. Kolch,et al.  Regulation and Role of Raf-1/B-Raf Heterodimerization , 2006, Molecular and Cellular Biology.

[46]  William B. Smith,et al.  Selective inhibition of BET bromodomains , 2010, Nature.

[47]  Derek Y. Chiang,et al.  The landscape of somatic copy-number alteration across human cancers , 2010, Nature.

[48]  Sydney L. Stoops,et al.  Inhibition of Akt with small molecules and biologics: historical perspective and current status of the patent landscape , 2011, Expert opinion on therapeutic patents.

[49]  David R. Liu,et al.  Highly Specific, Bi-substrate-Competitive Src Inhibitors from DNA-Templated Macrocycles , 2011, Nature chemical biology.

[50]  Scott A. Armstrong,et al.  MLL translocations, histone modifications and leukaemia stem-cell development , 2007, Nature Reviews Cancer.

[51]  C. Ly,et al.  Antagonists of inhibitor of apoptosis proteins based on thiazole amide isosteres. , 2010, Bioorganic & medicinal chemistry letters.

[52]  Richard Marais,et al.  The RAF proteins take centre stage , 2004, Nature Reviews Molecular Cell Biology.

[53]  Noel Southall,et al.  Evaluation of thieno[3,2-b]pyrrole[3,2-d]pyridazinones as activators of the tumor cell specific M2 isoform of pyruvate kinase. , 2010, Bioorganic & medicinal chemistry letters.

[54]  Matthew Meyerson,et al.  The Menin Tumor Suppressor Protein Is an Essential Oncogenic Cofactor for MLL-Associated Leukemogenesis , 2005, Cell.

[55]  J. Fletcher,et al.  BRD4-NUT fusion oncogene: a novel mechanism in aggressive carcinoma. , 2003, Cancer research.

[56]  Zhijian Zhao,et al.  Allosteric Akt (PKB) inhibitors: discovery and SAR of isozyme selective inhibitors. , 2005, Bioorganic & medicinal chemistry letters.

[57]  J. Acker,et al.  Brefeldin A acts to stabilize an abortive ARF-GDP-Sec7 domain protein complex: involvement of specific residues of the Sec7 domain. , 1999, Molecular cell.

[58]  Y Wang,et al.  Positional cloning of the gene for multiple endocrine neoplasia-type 1. , 1997, Science.

[59]  M. Wigler,et al.  Human Sos1: a guanine nucleotide exchange factor for Ras that binds to GRB2. , 1993, Science.

[60]  Gerald C. Chu,et al.  Oncogenic Kras Maintains Pancreatic Tumors through Regulation of Anabolic Glucose Metabolism , 2012, Cell.

[61]  Raymond E. Moellering,et al.  Direct inhibition of the NOTCH transcription factor complex , 2009, Nature.

[62]  A. Gingras,et al.  Histone Recognition and Large-Scale Structural Analysis of the Human Bromodomain Family , 2012, Cell.

[63]  Gideon Bollag,et al.  Biochemical and Functional Characterization of Germ Line KRAS Mutations , 2007, Molecular and Cellular Biology.

[64]  J. Cherfils,et al.  Structural snapshots of the mechanism and inhibition of a guanine nucleotide exchange factor , 2003, Nature.

[65]  A. Kral,et al.  Rapid assembly of diverse and potent allosteric Akt inhibitors. , 2008, Bioorganic & medicinal chemistry letters.

[66]  L. Vassilev Small-Molecule Antagonists of p53-MDM2 Binding: Research Tools and Potential Therapeutics , 2004, Cell cycle.

[67]  Kam Y. J. Zhang,et al.  Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma , 2010, Nature.

[68]  Kenneth Chu,et al.  Sustained Loss of a Neoplastic Phenotype by Brief Inactivation of MYC , 2002, Science.

[69]  Somasekar Seshagiri,et al.  Disruption of PH–kinase domain interactions leads to oncogenic activation of AKT in human cancers , 2012, Proceedings of the National Academy of Sciences.

[70]  A. Hopkins,et al.  The druggable genome , 2002, Nature Reviews Drug Discovery.

[71]  P. Hajduk,et al.  Predicting protein druggability. , 2005, Drug discovery today.

[72]  D. Barford,et al.  Wild-type and mutant B-RAF activate C-RAF through distinct mechanisms involving heterodimerization. , 2005, Molecular cell.

[73]  S. Schreiber,et al.  Macrolactones in diversity-oriented synthesis: preparation of a pilot library and exploration of factors controlling macrocyclization. , 2004, Journal of combinatorial chemistry.

[74]  C. Tse,et al.  ABT-263: a potent and orally bioavailable Bcl-2 family inhibitor. , 2008, Cancer research.

[75]  Qi Sun,et al.  Discovery of small molecules that bind to K-Ras and inhibit Sos-mediated activation. , 2012, Angewandte Chemie.

[76]  M. Steinmetz,et al.  Structural basis for the regulation of tubulin by vinblastine , 2005, Nature.

[77]  Kam Y. J. Zhang,et al.  Discovery of a selective inhibitor of oncogenic B-Raf kinase with potent antimelanoma activity , 2008, Proceedings of the National Academy of Sciences.

[78]  J. Reis-Filho,et al.  Kinase-Dead BRAF and Oncogenic RAS Cooperate to Drive Tumor Progression through CRAF , 2010, Cell.

[79]  J. Lippincott-Schwartz,et al.  Microtubule-dependent retrograde transport of proteins into the ER in the presence of brefeldin a suggests an ER recycling pathway , 1990, Cell.

[80]  G. Verdine,et al.  Stapled peptides for intracellular drug targets. , 2012, Methods in enzymology.

[81]  Gideon Bollag,et al.  GTPase activating proteins: critical regulators of intracellular signaling. , 2002, Biochimica et biophysica acta.

[82]  I. Bernstein,et al.  Molecular rearrangements of the MLL gene are present in most cases of infant acute myeloid leukemia and are strongly correlated with monocytic or myelomonocytic phenotypes. , 1994, The Journal of clinical investigation.

[83]  D. Barford,et al.  Mechanism of Activation of the RAF-ERK Signaling Pathway by Oncogenic Mutations of B-RAF , 2004, Cell.

[84]  Evripidis Gavathiotis,et al.  A stapled BIM peptide overcomes apoptotic resistance in hematologic cancers. , 2012, The Journal of clinical investigation.

[85]  Christopher L. McClendon,et al.  Reaching for high-hanging fruit in drug discovery at protein–protein interfaces , 2007, Nature.

[86]  H. Christofk,et al.  Identification of small molecule inhibitors of pyruvate kinase M2. , 2010, Biochemical pharmacology.

[87]  Maksymilian Chruszcz,et al.  Structural insights into inhibition of the bivalent menin-MLL interaction by small molecules in leukemia. , 2012, Blood.

[88]  Suzanne Schubbert,et al.  Hyperactive Ras in developmental disorders and cancer , 2007, Nature Reviews Cancer.

[89]  W. Herr,et al.  Leukemia Proto-Oncoprotein MLL Forms a SET1-Like Histone Methyltransferase Complex with Menin To Regulate Hox Gene Expression , 2004, Molecular and Cellular Biology.

[90]  R. Klausner,et al.  ADP-ribosylation factor, a small GTP-binding protein, is required for binding of the coatomer protein beta-COP to Golgi membranes. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[91]  Christopher P Austin,et al.  Evaluation of substituted N,N'-diarylsulfonamides as activators of the tumor cell specific M2 isoform of pyruvate kinase. , 2010, Journal of medicinal chemistry.

[92]  Jolanta Grembecka,et al.  Menin-MLL inhibitors reverse oncogenic activity of MLL fusion proteins in leukemia. , 2012, Nature chemical biology.

[93]  Stephen P. Hale,et al.  The exploration of macrocycles for drug discovery — an underexploited structural class , 2008, Nature Reviews Drug Discovery.

[94]  Michelle R Arkin,et al.  Discovery of a potent small molecule IL-2 inhibitor through fragment assembly. , 2003, Journal of the American Chemical Society.

[95]  C. Lindsley,et al.  Development of potent, allosteric dual Akt1 and Akt2 inhibitors with improved physical properties and cell activity. , 2008, Bioorganic & medicinal chemistry letters.

[96]  Huan Yang,et al.  The Akt/PKB pathway: molecular target for cancer drug discovery , 2005, Oncogene.

[97]  Kathleen Haskell,et al.  Allosteric inhibitors of Akt1 and Akt2: a naphthyridinone with efficacy in an A2780 tumor xenograft model. , 2008, Bioorganic & medicinal chemistry letters.

[98]  Ru Wei,et al.  The M2 splice isoform of pyruvate kinase is important for cancer metabolism and tumour growth , 2008, Nature.

[99]  B. R. Bowman,et al.  Inhibition of oncogenic Wnt signaling through direct targeting of β-catenin , 2012, Proceedings of the National Academy of Sciences.

[100]  Derek S. Tan,et al.  Expanding the range of 'druggable' targets with natural product-based libraries: an academic perspective. , 2010, Current opinion in chemical biology.

[101]  J. Rothman,et al.  Inhibition by brefeldin A of a Golgi membrane enzyme that catalyses exchange of guanine nucleotide bound to ARF , 1992, Nature.

[102]  Susan S. Taylor,et al.  Allosteric Activation of Functionally Asymmetric RAF Kinase Dimers , 2013, Cell.

[103]  Maxwell D Cummings,et al.  Discovery and cocrystal structure of benzodiazepinedione HDM2 antagonists that activate p53 in cells. , 2005, Journal of medicinal chemistry.

[104]  Daniel R. Caffrey,et al.  Structure-based maximal affinity model predicts small-molecule druggability , 2007, Nature Biotechnology.

[105]  S. Korsmeyer,et al.  An inhibitor of Bcl-2 family proteins induces regression of solid tumours , 2005, Nature.

[106]  Qiang Zhou,et al.  Recruitment of P-TEFb for stimulation of transcriptional elongation by the bromodomain protein Brd4. , 2005, Molecular cell.

[107]  M. Cleary,et al.  Meis1 is an essential and rate-limiting regulator of MLL leukemia stem cell potential. , 2007, Genes & development.

[108]  J. Aster,et al.  BRD–NUT oncoproteins: a family of closely related nuclear proteins that block epithelial differentiation and maintain the growth of carcinoma cells , 2008, Oncogene.

[109]  Roderick E Hubbard,et al.  Experiences in fragment-based lead discovery. , 2011, Methods in enzymology.

[110]  Monya Baker,et al.  Fragment-based lead discovery grows up , 2012, Nature Reviews Drug Discovery.

[111]  C. V. van Veelen,et al.  L-alpha-alanine inhibition of pyruvate kinase from tumors of the human central nervous system. , 1979, Cancer research.

[112]  Jonathan Goldberg,et al.  Crystal structure of ARF1*Sec7 complexed with Brefeldin A and its implications for the guanine nucleotide exchange mechanism. , 2003, Molecular cell.

[113]  O. Warburg,et al.  THE METABOLISM OF TUMORS IN THE BODY , 1927, The Journal of general physiology.

[114]  M. Cleary,et al.  A higher-order complex containing AF4 and ENL family proteins with P-TEFb facilitates oncogenic and physiologic MLL-dependent transcription. , 2010, Cancer cell.

[115]  Alex M. Clark,et al.  2D Structure Depiction , 2006, J. Chem. Inf. Model..

[116]  Qiang Zhou,et al.  Brd4 Recruits P-TEFb to Chromosomes at Late Mitosis To Promote G1 Gene Expression and Cell Cycle Progression , 2007, Molecular and Cellular Biology.

[117]  J. Drews Genomic sciences and the medicine of tomorrow , 1996, Nature Biotechnology.

[118]  P. Majumder,et al.  MK-2206, an Allosteric Akt Inhibitor, Enhances Antitumor Efficacy by Standard Chemotherapeutic Agents or Molecular Targeted Drugs In vitro and In vivo , 2010, Molecular Cancer Therapeutics.

[119]  Hieu T. Do,et al.  Demonstration of a genetic therapeutic index for tumors expressing oncogenic BRAF by the kinase inhibitor SB-590885. , 2006, Cancer research.